Doxycycline in Type II Diabetes
Doxycycline in Combination With Sitagliptin on the Glycemic and Cardiac Indices in Patients With Type 2 Diabetes Mellitus
1 other identifier
interventional
60
1 country
1
Brief Summary
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_1 diabetes-mellitus-type-2
Started Mar 2024
Longer than P75 for phase_1 diabetes-mellitus-type-2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 9, 2024
CompletedFirst Posted
Study publicly available on registry
March 26, 2024
CompletedStudy Start
First participant enrolled
March 30, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 20, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
April 20, 2026
CompletedApril 4, 2025
April 1, 2025
2 years
March 9, 2024
April 3, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Change in glycemic profile
measurement of fasting blood glucose (FBG)
3 months
Change in glycemic profile
measurement of glycated hemoglobin
3 months
Study Arms (2)
control group
ACTIVE COMPARATORpatients were on sitagliptin 100mg /day monotherapy
Comparative group
ACTIVE COMPARATORpatients were on sitagliptin 100mg /day monotherapy plus doxycycline 100 mg
Interventions
Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes
Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth.
Eligibility Criteria
You may qualify if:
- Male or female sex more than 40 years old Newly diagnosed type II diabetes. HbA1c more than 6.5
You may not qualify if:
- Patient with chronic kidney disease, hepatic disorders, mental and psychiatric disorders, pregnancy, and lactation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mostafa Bahaalead
Study Sites (1)
Tanta Unuversity
Tanta, 31527, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- NONE
- Masking Details
- open label
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Teaching assisstant
Study Record Dates
First Submitted
March 9, 2024
First Posted
March 26, 2024
Study Start
March 30, 2024
Primary Completion
March 20, 2026
Study Completion
April 20, 2026
Last Updated
April 4, 2025
Record last verified: 2025-04